Back to Search
Start Over
Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway epithelium of patients with COPD
- Source :
- Clinical Epigenetics, Clinical Epigenetics, Vol 9, Iss 1, Pp 1-10 (2017), Clinical Epigenetics, 9:42. BMC, Clinical Epigenetics, 9
- Publication Year :
- 2017
-
Abstract
- Background Goblet cell metaplasia, a common feature of chronic obstructive pulmonary disease (COPD), is associated with mucus hypersecretion which contributes to the morbidity and mortality among patients. Transcription factors SAM-pointed domain-containing Ets-like factor (SPDEF) and forkhead box protein A2 (FOXA2) regulate goblet cell differentiation. This study aimed to (1) investigate DNA methylation and expression of SPDEF and FOXA2 during goblet cell differentiation and (2) compare this in airway epithelial cells from patients with COPD and controls during mucociliary differentiation. Methods To assess DNA methylation and expression of SPDEF and FOXA2 during goblet cell differentiation, primary airway epithelial cells, isolated from trachea (non-COPD controls) and bronchial tissue (patients with COPD), were differentiated by culture at the air-liquid interface (ALI) in the presence of cytokine interleukin (IL)-13 to promote goblet cell differentiation. Results We found that SPDEF expression was induced during goblet cell differentiation, while FOXA2 expression was decreased. Importantly, CpG number 8 in the SPDEF promoter was hypermethylated upon differentiation, whereas DNA methylation of FOXA2 promoter was not changed. In the absence of IL-13, COPD-derived ALI-cultured cells displayed higher SPDEF expression than control-derived ALI cultures, whereas no difference was found for FOXA2 expression. This was accompanied with hypomethylation of CpG number 6 in the SPDEF promoter and also hypomethylation of CpG numbers 10 and 11 in the FOXA2 promoter. Conclusions These findings suggest that aberrant DNA methylation of SPDEF and FOXA2 is one of the factors underlying mucus hypersecretion in COPD, opening new avenues for epigenetic-based inhibition of mucus hypersecretion. Electronic supplementary material The online version of this article (doi:10.1186/s13148-017-0341-7) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
0301 basic medicine
lcsh:Medicine
CHRONIC RHINOSINUSITIS
Pulmonary Disease, Chronic Obstructive
Metaplasia
SPDEF
Promoter Regions, Genetic
Cells, Cultured
Genetics (clinical)
GENE-EXPRESSION
Interleukin-13
DNA methylation
Cell Differentiation
Middle Aged
respiratory system
Trachea
medicine.anatomical_structure
CpG site
Hepatocyte Nuclear Factor 3-beta
NASAL POLYPS
Female
Goblet Cells
medicine.symptom
TRANSCRIPTION FACTOR FOXA2
STEM-CELLS
lcsh:QH426-470
Bronchi
Biology
OBSTRUCTIVE PULMONARY-DISEASE
TH2 INFLAMMATION
03 medical and health sciences
Genetics
medicine
Humans
COPD
Epigenetics
Molecular Biology
Goblet cell
Proto-Oncogene Proteins c-ets
GOBLET CELL HYPERPLASIA
Research
lcsh:R
Epithelial Cells
Mucus
VIVO DIFFERENTIATION
respiratory tract diseases
lcsh:Genetics
030104 developmental biology
Gene Expression Regulation
MUCUS HYPERSECRETION
Immunology
Cancer research
Respiratory epithelium
CpG Islands
FOXA2
Developmental Biology
Subjects
Details
- Language :
- English
- ISSN :
- 18687075
- Database :
- OpenAIRE
- Journal :
- Clinical Epigenetics, Clinical Epigenetics, Vol 9, Iss 1, Pp 1-10 (2017), Clinical Epigenetics, 9:42. BMC, Clinical Epigenetics, 9
- Accession number :
- edsair.doi.dedup.....abcb4569de2f86eec1c1e2300f51c358